Fresenius Medical Care AG (ETR:FME)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.88B |
| Revenue (ttm) | 19.64B |
| Net Income (ttm) | 718.19M |
| Shares Out | 288.09M |
| EPS (ttm) | 2.44 |
| PE Ratio | 16.91 |
| Forward PE | 10.12 |
| Dividend | 1.44 (3.49%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 548,511 |
| Average Volume | 776,787 |
| Open | 41.25 |
| Previous Close | 41.14 |
| Day's Range | 41.10 - 41.37 |
| 52-Week Range | 39.10 - 54.02 |
| Beta | 0.95 |
| RSI | 42.60 |
| Earnings Date | Nov 4, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial StatementsNews
Fresenius Medical Care: 'Buy' Again Following A Peak In May
Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to d...
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Performance
Q3 2025 Fresenius Medical Care AG Earnings Call Transcript
Q3 2025 Fresenius Medical Care AG Earnings Call Transcript
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care is Now Oversold (FMS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Fresenius Medical Care (FMS) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Fresenius Medical Care (Symbol: FMS) crossed below their 200 day moving average of $25.80, changing hands as low as $23.68 per share. Fresenius Medical Care shares are...
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at cons...
Fresenius Medical Care Q3 Results Climb, Maintains FY25 Outlook
(RTTNews) - Fresenius Medical Care AG (FMS, FME.DE) reported Tuesday higher profit and revenues in its third quarter, and maintained fiscal 2025 outlook.
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take ...
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation...
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hof...
FMS Crosses Below Key Moving Average Level
In trading on Thursday, shares of Fresenius Medical Care (Symbol: FMS) crossed below their 200 day moving average of $25.27, changing hands as low as $25.06 per share. Fresenius Medical Care shares ar...
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set d...
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical...
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/10...
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care sees limited impact from tariffs, says CEO
Helen Giza, Fresenius Medical CEO discusses the impact of tariffs on the business